about
An infinitely expandable cloning strategy plus repeat-proof PCR for working with multiple shRNA.Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells.Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, CanadaPeriacinar stellate shaped cells in rat pancreas: identification, isolation, and culture.Multiple shRNA combinations for near-complete coverage of all HIV-1 strainsVirological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.Dynamics of HCV RNA levels during acute hepatitis C virus infection.Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studySequencing of the Hepatitis C Virus: A Systematic Review.Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionNaturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individualsA quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 studyHIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infectionPlasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.96 shRNAs designed for maximal coverage of HIV-1 variants.Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success.Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.Historical Trends in the Hepatitis C Virus Epidemics in North America and AustraliaHCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
P50
Q33388241-07C84D70-EB02-4189-A237-6F6701BEAD27Q33489590-D9F236FB-F345-4DC2-9104-1454A8FEB097Q33795847-FE0E6F19-ED51-4A63-913A-E3FAEEAB3774Q34164063-8E38A2C8-8F90-4E2E-860A-B7DC55E67A11Q34221633-9821FF90-3ADE-4DAF-B117-5BF789E8A917Q34415820-BDE308B5-0502-48D7-9EF1-33E0BE00A7B7Q34475071-10C05F9F-EABF-48B5-9BB5-635E094692E0Q34552467-0C3B066B-E202-4531-8B8E-9AE816BBF0BDQ34714349-195D53ED-7461-458F-AEF1-5DF02627CA00Q34771346-687B9BDC-BBF6-4E4E-9853-FEAC91B51C1FQ34785317-2A433C6D-E6E0-4D47-925C-BDF49CC4F239Q34796385-2C18E6DF-3D48-4AAE-BC93-F0A6A11A7A24Q35053399-49D86414-92DA-4FB4-8E16-50661D311422Q35061753-39057FD3-67FF-4CAF-962A-00EB0783BA58Q35102600-14775459-5DEA-4F33-90DD-85A24E343EFFQ35191116-FD813AC4-EE61-4710-A4AC-0E539F80D45FQ35249648-2C75EEB3-3D2F-4118-AC9C-1E5338C879E7Q35698428-513EA45D-8D6F-468A-8F15-2FB4317E45AFQ35703205-DDAB1B3C-659D-4E93-B79F-BA66FF546632Q35832850-9BD419C6-802F-4420-B4C7-2A76A8FCB846Q36035679-1714466B-E237-4507-97EC-D6F9848A0512Q36120059-873A1C48-7110-4DD8-86A0-F6DB1A4F5000Q36134478-752AEDF9-A84C-4612-83CF-512E653BE706Q36506119-45344639-7DEC-4877-8222-B244FFC944A3Q36611680-5DA90331-DAED-4FE2-A933-30CF9A0294A5Q36874661-30A36344-0903-463B-AC9D-A62995D2CD4BQ36922133-CB4778B6-7C1F-40B9-978A-FDC6CD9B9DC6Q37233732-C17ACFB4-523A-4C87-BB0B-1666C3A995E4Q37417692-0ADB3DAC-D60C-457A-B9EB-0EC22515879CQ37615174-9D15861A-4C70-43BE-A2C3-8BAF606841DBQ38381584-4CB1555B-372A-4EB9-9226-1B2CC653FE20Q38721242-2DBA8602-E3E4-4381-B705-BCD3E297F1EAQ38992902-6F935E7C-DE24-43FB-98DA-B71F2ADE1F22Q39157096-C2B1D595-1CE3-4EB6-B9FF-00DFBDF04538Q39221144-3F1C164D-4D2C-43A3-AEC1-11D23314C15FQ39403799-E5F2233C-80D5-4895-8B96-B0BF696B1B42Q39403806-F37990EA-F079-48CE-9BAB-E4046133474CQ40069643-B3116CDE-E834-4487-B633-E9D1457CC27AQ40118634-F5AB7F2D-0C7C-4E1B-8D8C-1C1C0DBD4832Q40196486-B7436E43-1DD4-4931-9339-9AE009A6548D
P50
description
researcher ORCID ID = 0000-0002-8657-4261
@en
wetenschapper
@nl
name
Tanya Applegate
@ast
Tanya Applegate
@en
Tanya Applegate
@es
Tanya Applegate
@nl
type
label
Tanya Applegate
@ast
Tanya Applegate
@en
Tanya Applegate
@es
Tanya Applegate
@nl
prefLabel
Tanya Applegate
@ast
Tanya Applegate
@en
Tanya Applegate
@es
Tanya Applegate
@nl
P106
P1153
7003993403
P31
P496
0000-0002-8657-4261